iDNA Genomics Public Ltd
CCSECY:IDNA10.00
EUR
-1.00
(-9.09%)
ISIN
CY0109800710
Return %
Stock
S&P 500
1Y
-65.99
14.20
3Y
-62.96
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nicosia Cyprus
- IPO Date
- Dec 17, 2021
- Website
- idnagenomicsplc.com
- Similar Companies
- Business
- iDNA Genomics Public Ltd is a biotechnology and precision medicine company specializing in genomic analysis, molecular diagnostics, and personalized healthcare solutions. Incorporated in 2020 and headquartered in Nicosia, Cyprus, the company operates primarily through its operating subsidiaries, iDNA Genomics I.K.E. and iDNA Laboratories I.K.E., located in Kifissia, Greece. The company develops and commercializes specialized genetic testing kits and digital bioinformatics tools that translate genomic data into actionable preventative, therapeutic, and wellness strategies for healthcare professionals, clinical institutions, pharmacies, and consumers across European and international markets. The company's product and service portfolio encompasses a comprehensive suite of clinical and lifestyle genetic testing panels; pharmacogenomic screening solutions, highlighted by the iDNA PGx CNS Test, which evaluates patient-specific genetic variations to guide medication selection, optimize dosage, and minimize adverse reactions for central nervous system therapies; disease risk and preventative diagnostics, including the iDNA Cardio Health test for assessing genetic predispositions to cardiovascular conditions; nutrigenetic profiling, anchored by the CE-marked iDNA NutriGenetix panel, which analyzes metabolic traits, nutrient absorption, food sensitivities, and weight management markers; sports genomics, offering genetic assessments of muscular performance, endurance capacity, and soft-tissue injury susceptibility; biological age assessment, featuring the BioAge test that measures physiological senescence relative to chronological age; and digital health infrastructure via myEMR, a proprietary cloud-based medical records platform that facilitates sample registration, laboratory tracking, and secure delivery of clinical genetic reports. In recent developments, iDNA Genomics Public Ltd has executed key capital structure and operational adjustments on the Emerging Companies Market of the Cyprus Stock Exchange. In March 2026, the company admitted new ordinary shares following the conversion of a portion of its 8.5% convertible bonds due 2028 (CSE: IDNAB28). Operationally, the company has leveraged strategic commercial agreements, including distribution alliances with pharmaceutical partners such as the VIANEX Group, to expand retail pharmacy and clinical channel access for its testing kits. Concurrently, the organization has focused on optimizing its central laboratory operations in Greece, managing regulatory reporting compliances under the Cyprus Stock Exchange, and advancing research collaborations to support clinical validation and market uptake of its preventative genomics portfolio.